Empagliflozin is an SGLT2 inhibitor used in the treatment of type 2 diabetes mellitus, heart failure, and chronic kidney disease. It reduces blood glucose by inhibiting glucose reabsorption in the renal proximal tubules, leading to increased urinary glucose excretion and improved cardiovascular outcomes.
Reviews
There are no reviews yet.